ArticleFrontiers in endocrinology2025
Association between triglyceride-glucose index and the risk of cardiometabolic diseases in metabolically healthy obese individuals: a prospective cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- C-reactive protein-triglyceride-glucose index (CTI) as a predictor of chronic liver disease in adults with macrocytic anemia.Scientific reports · 2026Article
- Harnessing Clinical and Biochemical Data for Personalized Cardiovascular Risk Prediction: a Machine Learning Approach Toward Precision Nutrition.The Journal of nutrition · 2026Observational
- Cross-sectional associations of metabolic risk indices and cardiometabolic multimorbidity among adults with depressive symptoms: evidence from China and the United Kingdom.Archives of medical science : AMS · 2026Article
- Assessment of cholesterol-HDL-glucose index in anticipating risk of cardiometabolic diseases: a comparative study with triglyceride-glucose index.Scientific reports · 2025Article
- Insulin resistance-related indices, genetic risk, and the risk of cardiovascular disease in individuals with preclinical or clinical obesity: a large prospective cohort study in the UK biobank.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolically healthy obese (MHO) individuals meet the criteria for obesity with normal blood glucose and lipid metabolism parameters, absence of hypertension, and no concurrent cardiovascular diseases. However, the association between the triglyceride-glucose (TyG) index and the risk of cardiometabolic disease (CMD) in MHO individuals remains unclear. Methods and results: This study included obese individuals who underwent health examinations at Kailuan Group from 2006 to 2010, whom without a history of hypertension, diabetes, hyperlipidemia, cardiovascular disease, as the study participants. A total of 4750 participants were included in this study. The TyG index was calculated as ln[TG (mg/dL) × FPG (mg/dL)/2] and divided into four groups based on quartiles: Q1 group (<8.18); Q2 group (8.18-8.41); Q3 group (8.42-8.62); Q4 group (≥8.63). The Cox proportional hazards model was used to assess the relationship between the TyG index and risk of CMD incidence. During a median follow-up period of 11 (IQR 10.3, 11.2) years, 826 participants experienced CMD, among whom 131 participants developed coronary heart disease, 215 participants developed stroke, and 542 participants developed diabetes. After adjusting for multiple confounding factors, compared with the Q1 group, the adjusted HRs (95% CI) for CMD in the Q2-Q4 groups were 1.33 (1.03, 1.65), 1.37 (1.04, 1.82), and 2.04 (1.56, 2.68) ( Conclusions: A high TyG index increases the risk of CMD in MHO individuals. Monitoring and maintaining an appropriate TyG index may contribute to the prevention of CMD risk in MHO individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.